Mallinckrodt (OTCPK:MNKT.Q) - Hisse Senedi Fiyatı, Haberler ve Analizler

MNKT.Q Stoklara Genel Bakış

Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. Daha fazla detay

MNKT.Q temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	1/6
Temettüler	0/6

Risk Analizi

Anlamlı bir piyasa değeri yok ( $936K )

Negatif hissedar öz sermayesi

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

1 yıldan az nakit akışı var

Mallinckrodt plc Rakipler

AmeriCann

OTCPK:ACAN

US$523.8k

Sybleu

OTCPK:SYBE

US$583.7k

Panacea Life Sciences Holdings

OTCPK:PLSH

US$2.1m

60 Degrees Pharmaceuticals

NasdaqCM:SXTP

US$1.6m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Mallinckrodt
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.12
52 Haftanın En Yüksek Seviyesi	US$12.15
52 Haftanın En Düşük Seviyesi	US$0.026
Beta	0
11 Aylık Değişim	220.00%
3 Aylık Değişim	-79.26%
1 Yıllık Değişim	-98.99%
33 Yıllık Değişim	n/a
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-99.35%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	MNKT.Q	US Pharmaceuticals	US Pazar
7D	33.3%	1.6%	2.2%
1Y	-99.0%	10.0%	31.7%

Getiri vs. Endüstri: MNKT.Q geçen yıl % 10 oranında getiri sağlayan US Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: MNKT.Q geçen yıl % 31.7 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is MNKT.Q's price volatile compared to industry and market?
MNKT.Q volatility
MNKT.Q Average Weekly Movement	45.0%
Pharmaceuticals Industry Average Movement	9.7%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: MNKT.Q hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: MNKT.Q 'nin haftalık oynaklığı son bir yılda 77% dan 45% a düştü, ancak hâlâ US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1867	2,687	Siggi Olafsson	www.mallinckrodt.com

Mallinckrodt plc Temel Bilgiler Özeti

Mallinckrodt'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
MNKT.Q temel i̇stati̇sti̇kler
Piyasa değeri	US$936.02k
Kazançlar(TTM)	-US$2.97b
Gelir(TTM)	US$1.89b

0.0x

P/S Oranı

0.0x

F/K Oranı

MNKT.Q aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
MNKT.Q gelir tablosu (TTM)
Gelir	US$1.89b
Gelir Maliyeti	US$1.25b
Brüt Kâr	US$640.60m
Diğer Giderler	US$3.61b
Kazançlar	-US$2.97b

Son Raporlanan Kazançlar

Sep 29, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-222.21
Brüt Marj	33.97%
Net Kâr Marjı	-157.55%
Borç/Özkaynak Oranı	-34.4%

MNKT.Q uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

MNKT.Q Stoklara Genel Bakış

Risk Analizi

Mallinckrodt plc Rakipler

OTCPK:ACAN

US$523.8k

OTCPK:SYBE

US$583.7k

OTCPK:PLSH

US$2.1m

NasdaqCM:SXTP

US$1.6m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Mallinckrodt plc Presents Data on Terlipressin for Injection in Patients with Hepatorenal Syndrome at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Mallinckrodt plc Presents Data on Terlipressin (Terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) At Kidney Week 2024

Mallinckrodt plc to Report Q3, 2024 Results on Nov 05, 2024

Mallinckrodt plc Announces Publication of Human Factors Studies and Arthritis Foundation Ease of Use®? Certification of Acthar®? Gel (repository Corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector

CVC Capital Partners Fund IX managed by CVC Capital Partners plc (ENXTAM:CVC) entered into a definitive agreement to acquire Therakos business of Mallinckrodt from Mallinckrodt plc for approximately $925 million.

Mallinckrodt plc to Report Q2, 2024 Results on Aug 06, 2024

Recent updates

Mallinckrodt plc Presents Data on Terlipressin for Injection in Patients with Hepatorenal Syndrome at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Mallinckrodt plc Presents Data on Terlipressin (Terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) At Kidney Week 2024

Mallinckrodt plc to Report Q3, 2024 Results on Nov 05, 2024

Mallinckrodt plc Announces Publication of Human Factors Studies and Arthritis Foundation Ease of Use®? Certification of Acthar®? Gel (repository Corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector

CVC Capital Partners Fund IX managed by CVC Capital Partners plc (ENXTAM:CVC) entered into a definitive agreement to acquire Therakos business of Mallinckrodt from Mallinckrodt plc for approximately $925 million.

Mallinckrodt plc to Report Q2, 2024 Results on Aug 06, 2024

Mallinckrodt plc Presents Data on Terlipressin for Injection in Patients with Hepatorenal Syndrome at the 2024 European Association for the Study of the Liver (EASL) Congress

Mallinckrodt plc Reaffirms Financial Guidance for the Full Year of 2024

Mallinckrodt plc, Annual General Meeting, May 09, 2024

Mallinckrodt plc Provides Earnings Guidance for the Year 2024

Mallinckrodt Appoints Paul O'neill as Executive Vice President, Quality & Operations, Specialty Brands

Mallinckrodt plc Announces FDA Clearance of the INOmax® EVOLVE™ DS Delivery System and Approval of the INOmax® Mini-Cylinder

Mallinckrodt plc to Present Breadth of Data on Terlivaz (Terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome At the American Association for the Study of Liver Diseases (Aasld) 2023 Liver Meeting

Mallinckrodt plc Revises Earnings Guidance for the Full-Year of 2023

Mallinckrodt Presents Latest Health Economics Data on Acthar Gel (Repository Corticotropin Injection) At the Academy of Managed Care Pharmacy (AMCP) Nexus 2023

Mallinckrodt Announces Publication of Two Journal Manuscripts with Clinical and Economic Evidence for Acthar Gel (Repository Corticotropin Injection)

Mallinckrodt Reportedly Considers Sale of Opioid Business

Mallinckrodt plc Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate Capsules and Launches Product Used to Treat Attention-Deficit/Hyperactivity Disorder (ADHD)

Mallinckrodt plc(OTCPK:MNKT.Q) dropped from S&P TMI Index

NYSE American to Commence Delisting Proceedings Against Mallinckrodt

Mallinckrodt plc Filed for Bankruptcy

Mallinckrodt plc is Heading Towards Bankruptcy

Mallinckrodt plc Contemplates Bankruptcy

Mallinckrodt plc Reaffirms Sales Guidance for the Full-Year 2023

Pomerantz LLP Announces That a Class Action Lawsuit Has Been Filed Against Mallinckrodt plc

Alta Fundamental Requests Mallinckrodt to Convene an Extraordinary General Meeting

Mallinckrodt to Present Data on Terlivaz® (Terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome

Mallinckrodt Announces Publication of Real-World Data on the Use of Extracorporeal Photopheresis (ECP) in Heart Transplant Patients

Mallinckrodt plc Presents Clinical Data for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS) at the American Transplant Congress (ATC) 2023

Mallinckrodt plc Provides Earnings Guidance for the Year 2023

Mallinckrodt plc to Report Q4, 2022 Results on Feb 28, 2023

Mallinckrodt plc Presents New TERLIVAZ® for Injection Data on Hepatorenal Syndrome Reversal at the Society of Critical Care Medicine 2023 Critical Care Congress

Mallinckrodt plc Announces Appointment of Peter Richardson as Chief Scientific Officer

Mallinckrodt plc Provides Financial Guidance for the Full-Year 2022

Mallinckrodt to Present Data on Terlivaz® (Terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (Hrs) At the American Society of Nephrology (Asn) Kidney Week 2022 Scientific Meeting

Mallinckrodt plc NEW SHS Deleted from OTC Equity

Mallinckrodt plc to Report Q3, 2022 Results on Nov 08, 2022

Mallinckrodt plc Appoints Karen L. Ling as Human Resources and Compensation Committee of the Board

Mallinckrodt plc Appoints Susan Silbermann to Its Board of Directors

Mallinckrodt plc Announces Submission of 510(k) to the U.S. FDA for Inhaled Nitric Oxide Delivery System

Mallinckrodt plc Announces Appointment of Lisa French as Executive Vice President and Chief Commercial Officer, Effective October 1, 2022

Mallinckrodt Receives U.S. FDA Approval for Terlivaz (Terlipressin) for Injection for the Treatment of Hepatorenal Syndrome (HRS)

Mallinckrodt plc, Annual General Meeting, Sep 29, 2022

Mallinckrodt plc Provides Update on Executive Committee

Mallinckrodt plc Provides Revenue Guidance for the Full Year of 2022

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Mallinckrodt plc Temel Bilgiler Özeti

0.0x

0.0x

Kazanç ve Gelir